IOVA · XBRL financial data

Iovance Biotherapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IOVA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0	0*	1	31	59	74*	49	60	67	87*	71	99
Cost of revenue	4	4*	7	31	40	46*	50	57	38	43*	42	44
Research and development	88	87*	80	62	68	72*	77	79	75	71*	62	59
General and administrative	27	30*	31	40	40	43*	44	38	35	36*	39	39
Operating income (loss)	(118)	(121)*	(118)	(102)	(89)	(87)*	(121)	(114)	(95)	(73)*	(81)	(52)
Interest income	3	3*	3	3	4	10*	3	4	1	2*	1	3
Income tax expense (benefit)	(1)	(2)*	(1)	(1)	(2)	2*	(2)	2	(2)	0*	(1)	(1)
Net income (loss)	(114)	(116)*	(113)	(97)	(84)	(79)*	(116)	(112)	(91)	(72)*	(79)	(47)
Earnings per share, basic USD per share	(0.46)	—	(0.42)	(0.34)	(0.28)	—	(0.36)	(0.33)	(0.25)	—	(0.19)	(0.11)
Earnings per share, diluted USD per share	(0.46)	—	(0.42)	(0.34)	(0.28)	—	(0.36)	(0.33)	—	—	(0.19)	(0.11)
Weighted average shares, basic millions of shares	246	—	266	0	0	—	0	0	0	0*	0	0
Weighted average shares, diluted millions of shares	246	—	266	0	0	—	0	0	—	—	0	0

Fiscal quarters (IOVA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	268	115	134	229	164	116	172	132	158	163	197	111
Short-term investments	94	165	222	184	233	208	188	169	143	134	117	187
Marketable securities	94	165	222	184	233	208	188	169	143	134	117	187
Accounts receivable	—	0	0	32	56	69	71	60	67	82	82	102
Inventory	9	10	18	28	39	52	66	50	52	52	58	56
Prepaid and other current assets	12	17	11	10	7	12	16	12	10	12	13	9
Total current assets	383	308	386	482	499	457	513	423	429	443	467	464
Property and equipment, net	113	114	112	111	113	109	112	122	127	131	131	131
Right-of-use asset	66	63	72	69	67	55	51	50	49	46	44	43
Total assets	852	780	870	964	991	910	967	907	905	913	926	916
Accounts payable	19	33	26	20	32	28	28	32	31	22	37	26
Accrued liabilities	61	69	46	62	75	82	85	89	87	111	88	78
Total current liabilities	91	110	83	94	118	122	123	129	126	138	129	107
Lease liability, non-current	68	67	72	69	66	44	44	45	45	44	44	43
Total liabilities	178	196	190	196	218	200	199	209	203	215	204	179
Accumulated deficit	(1,896)	(2,012)	(2,125)	(2,222)	(2,306)	(2,385)	(2,501)	(2,612)	(2,704)	(2,776)	(2,855)	(2,902)
Total stockholders' equity	674	585	680	769	773	710	768	698	702	699	722	736
Total liabilities and equity	852	780	870	964	991	910	967	907	905	913	926	916
Common shares outstanding (cover page) millions of shares	256	279	280	304	305	328	334	362	397	412	447	453

Fiscal quarters (IOVA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(114)	(116)*	(113)	(97)	(84)	(79)*	(116)	(112)	(91)	(72)*	(79)	(47)
Stock-based compensation	16*	14*	17	30*	31	31*	23	15	12	12*	11	12
Depreciation and amortization	3	3*	3	3	3	3*	3	3	3*	4*	3	4*
Net cash from operating activities	(84)*	(84)*	(122)	(98)*	(59)*	(73)*	(104)	(67)*	(79)*	(53)*	(72)	(61)*
Purchases of property and equipment	4*	4*	4	0*	2*	4*	6	7*	11*	9*	7	5*
Net cash from investing activities	(79)*	(73)*	(112)	40*	(49)*	24*	16	14*	17*	1*	11	(74)*
Proceeds from issuing common stock	203*	0*	198	152*	48*	0*	149	13*	89*	56*	99	50*
Net cash from financing activities	203*	1*	194	153*	42*	2*	143	13*	88*	56*	94	49*
Net change in cash	38*	(153)*	(41)	94*	(65)*	(48)*	56	(40)*	26*	5*	33	(86)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Opko Health	301	164	(44)*	746.3M	6.9 quarters	Q2 FY26 10-Q/AJun 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	45	51	(56)*	74.4M	6.8 quarters	Q2 FY26 10-QJun 30, 2026
Dynavax Technologies	160	95	34*	117.4M	—	Q3 FY25 10-QSep 30, 2025
Evolus	45	84	(3.6)*	66.1M	12.6 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.